The high diagnostic performance of NfL, with good correlation with age and cognitive decline, in addition to its stability in pre-analytical handling and the fact that it can be measured by a robust assay used in clinical routine in many European countries, has pointed to plasma NfL as the best biomarker for diagnosis of AD in DS. This evidence concerns the gene NEFL and Alzheimer disease.